{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:38:39Z","timestamp":1792557519216,"version":"4.5.0"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jtha.2026.09.039","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:23:28Z","timestamp":1791008608000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fragility analysis should complement statistical reporting in thrombosis trials: lessons from reduced-dose direct oral anticoagulants for cancer-associated venous thromboembolism"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6195-8624","authenticated-orcid":false,"given":"Ronald","family":"Chow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeet","family":"Talwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manu","family":"Beniwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jameel","family":"Abdulrehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2026.09.039_bib1","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jclinepi.2013.10.019","article-title":"The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index","volume":"67","author":"Walsh","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jtha.2026.09.039_bib2","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(19)30338-9","article-title":"The fragility of phase 3 trials supporting FDA-approved anticancer medicines: a retrospective analysis","volume":"20","author":"Del Paggio","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtha.2026.09.039_bib3","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ophtha.2017.11.015","article-title":"Fragility of results in ophthalmology randomized controlled trials: a systematic review","volume":"125","author":"Shen","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtha.2026.09.039_bib4","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1097\/BPO.0000000000001201","article-title":"The fragility of statistically significant results in pediatric orthopaedic randomized controlled trials as quantified by the Fragility Index: a systematic review","volume":"38","author":"Khormaee","year":"2018","journal-title":"J Pediatr Orthop"},{"key":"10.1016\/j.jtha.2026.09.039_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2026.106844","article-title":"Direct oral anticoagulants in cancer-associated venous thromboembolism: trial robustness and clinical trade-offs","volume":"10","author":"Zuin","year":"2026","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.09.039_bib6","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jtha.2025.09.026","article-title":"Reduced vs full-dose direct oral anticoagulants for extended treatment of cancer-associated venous thromboembolism: a systematic review and meta-analysis of randomized trials","volume":"24","author":"de Lucena","year":"2026","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.09.039_bib7","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa2416112","article-title":"Extended reduced-dose apixaban for cancer-associated venous thromboembolism","volume":"392","author":"Mah\u00e9","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.09.039_bib8","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jtha.2024.03.011","article-title":"Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial","volume":"22","author":"McBane","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.09.039_bib9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0140-6736(24)02842-3","article-title":"Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial","volume":"405","author":"Couturaud","year":"2025","journal-title":"Lancet"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362600629X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362600629X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:44:52Z","timestamp":1792554292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153878362600629X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":9,"alternative-id":["S153878362600629X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2026.09.039","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fragility analysis should complement statistical reporting in thrombosis trials: lessons from reduced-dose direct oral anticoagulants for cancer-associated venous thromboembolism","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2026.09.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}